Analysts Set STAAR Surgical Company (NASDAQ:STAA) Target Price at $20.67

Shares of STAAR Surgical Company (NASDAQ:STAA) have received an average rating of “Reduce” from the eleven research firms that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating and ten have given a hold rating to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $20.6667.

A number of equities research analysts have recently commented on the stock. Piper Sandler reiterated a “neutral” rating on shares of STAAR Surgical in a report on Monday, October 27th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of STAAR Surgical in a research report on Wednesday, October 8th. Canaccord Genuity Group reissued a “hold” rating and issued a $28.00 target price on shares of STAAR Surgical in a report on Tuesday, October 21st. Mizuho boosted their price target on STAAR Surgical from $17.00 to $18.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 16th. Finally, Stifel Nicolaus set a $28.00 price target on STAAR Surgical and gave the company a “hold” rating in a report on Thursday, August 7th.

STAAR Surgical Stock Performance

Shares of STAA stock opened at $26.55 on Friday. The company has a market capitalization of $1.31 billion, a price-to-earnings ratio of -13.76 and a beta of 0.92. STAAR Surgical has a one year low of $13.50 and a one year high of $31.36. The company’s 50-day moving average is $26.76 and its 200 day moving average is $22.30.

Institutional Trading of STAAR Surgical

Institutional investors have recently made changes to their positions in the stock. Armistice Capital LLC raised its holdings in shares of STAAR Surgical by 244.0% during the first quarter. Armistice Capital LLC now owns 3,000,000 shares of the medical instruments supplier’s stock valued at $52,890,000 after purchasing an additional 2,128,000 shares during the last quarter. Broadwood Capital Inc. grew its position in STAAR Surgical by 14.8% in the 1st quarter. Broadwood Capital Inc. now owns 12,455,264 shares of the medical instruments supplier’s stock worth $219,586,000 after purchasing an additional 1,606,633 shares during the period. Yunqi Capital Ltd grew its position in STAAR Surgical by 152.5% in the 1st quarter. Yunqi Capital Ltd now owns 1,937,589 shares of the medical instruments supplier’s stock worth $34,160,000 after purchasing an additional 1,170,176 shares during the period. Alpine Associates Management Inc. purchased a new stake in STAAR Surgical during the 3rd quarter valued at $24,535,000. Finally, Resona Asset Management Co. Ltd. lifted its holdings in shares of STAAR Surgical by 44.6% during the 1st quarter. Resona Asset Management Co. Ltd. now owns 2,169,618 shares of the medical instruments supplier’s stock valued at $38,358,000 after buying an additional 669,430 shares during the period. Hedge funds and other institutional investors own 96.70% of the company’s stock.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.